Astrazeneca ADR Stock
€61.00
Your prediction
Financial data and news for AstraZeneca
sharewise wants to provide you with the best news and tools for AstraZeneca, so we directly link to the best financial data sources.
Financials
News
How Does D-Wave Stack Up Against Quantum Competitors?
D-Wave Quantum Inc. (NYSE: QBTS) has emerged as one of the most talked-about stocks in the quantum computing industry, a space investors are watching
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies
AstraZeneca is bolstering its presence in the Chinese healthcare sector through a strategic acquisition worth $160 million, purchasing FibroGen's Chinese subsidiary. The deal, structured with an
Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Just when you may have finally gotten your head around the opportunity in artificial intelligence (AI), a new investment opportunity has popped up. Quantum computing is the latest “new thing”
3 Promising Growth Stocks You Can Buy for Less Than $100
Investing in growth stocks is a great way to grow your portfolio in the long run. But it can be difficult to predict which ones will take off in value and which one's won't. And that's why it might
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear
3 No-Brainer Growth Stocks to Buy for Less Than $100
Don't let the sell-off in the markets scare you off: Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many great stocks you can
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. But which stocks are likely to deliver growth over the
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're
Why AstraZeneca Topped the Market on Thursday
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q4 2024 Earnings CallFeb 06, 2025, 6:00 a.m. ET
Operator
Source Fool.com
3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices
Dividend stocks trading at discounted prices can make for great investments if you're willing to be patient. That's because, assuming their payouts are sustainable, you can lock in a higher yield
3 Cheap Growth Stocks to Buy in 2025
As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't